Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma

Trial Profile

Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs RG 4733 (Primary) ; Bevacizumab
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Dec 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 13 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top